aTyr Pharma, Inc. (NASDAQ:ATYR) Downgraded by RBC Capital
aTyr Pharma, Inc.(US:ATYR) Financial Modeling Prepยท2025-09-16 05:03RBC Capital downgraded aTyr Pharma to "Sector Perform" from "Outperform" following the Phase III EFZO-FIT study results of Efzofitimod.The stock experienced a significant decrease of 83.17%, reflecting investor reactions to the study outcomes and the downgrade.aTyr Pharma's market capitalization stands at approximately $99.46 million, highlighting the volatility and challenges in the biotech sector, especially for companies focusing on rare diseases.aTyr Pharma, Inc. (NASDAQ:ATYR) is a biotechnology company ...